The surge in demand for GLP-1 weight-loss medications is causing significant supply constraints and restructuring pharmaceutical production lines. Manufacturers are committing billions to acquire production assets and expand aseptic packaging facilities.
Economic Ripple Effects Across Healthcare
Insurers and health systems are evaluating long-term budget implications as coverage demands surge. The drug class is also driving increased clinical research into secondary metabolic and cardiovascular benefits.